2.20

2.22% -0.05

Iovance Biotherapeutics Inc (IOVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt IOVA? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.25

Offen:

$2.24

24-Stunden-Volumen:

10.59M

Relative Volume:

0.79

Marktkapitalisierung:

$873.33M

Einnahmen:

$241.53M

Nettoeinkommen (Verlust:

$-389.92M

KGV:

-1.7886

EPS:

-1.23

Netto-Cashflow:

$-323.54M

1W Leistung:

+0.00%

1M Leistung:

-13.39%

6M Leistung:

-4.76%

1J Leistung:

-72.36%

1-Tages-Spanne:

$2.17

$2.26

1-Wochen-Bereich:

$2.16

$2.34

52-Wochen-Spanne:

$1.6385

$8.15

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Firmenname

Iovance Biotherapeutics Inc

Sektor

Healthcare (1123)

Branche

Biotechnology (627)

Telefon

(650) 260-7120

Adresse

825 INDUSTRIAL ROAD, SAN CARLOS

Mitarbeiter

838

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

IOVA's Discussions on Twitter

Vergleichen Sie IOVA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IOVA Iovance Biotherapeutics Inc	2.20	893.18M	241.53M	-389.92M	-323.54M	-1.23
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-15	Herabstufung	Goldman	Neutral → Sell
2025-05-16	Herabstufung	UBS	Buy → Neutral
2025-05-12	Herabstufung	Truist	Buy → Hold
2025-05-09	Herabstufung	Citizens JMP	Mkt Outperform → Mkt Perform
2024-10-24	Eingeleitet	UBS	Buy
2024-07-29	Herabstufung	Piper Sandler	Overweight → Neutral
2023-11-20	Eingeleitet	Goldman	Buy
2023-09-18	Bestätigt	Barclays	Overweight
2023-05-30	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-27	Fortgesetzt	Wells Fargo	Equal Weight
2023-01-27	Hochstufung	Piper Sandler	Neutral → Overweight
2022-12-09	Herabstufung	Goldman	Buy → Neutral
2022-10-31	Eingeleitet	Guggenheim	Neutral
2022-08-18	Fortgesetzt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Stifel	Hold → Buy
2021-12-07	Fortgesetzt	Cowen	Outperform
2021-06-10	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Herabstufung	Piper Sandler	Overweight → Neutral
2021-05-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Herabstufung	Stifel	Buy → Hold
2021-05-03	Eingeleitet	Truist	Buy
2021-04-16	Eingeleitet	Goldman	Buy
2021-03-08	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-10-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-22	Eingeleitet	Mizuho	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-02-26	Bestätigt	H.C. Wainwright	Buy
2020-02-26	Bestätigt	Oppenheimer	Outperform
2019-12-18	Eingeleitet	JMP Securities	Mkt Outperform
2019-10-01	Eingeleitet	Stifel	Buy
2019-04-29	Eingeleitet	Piper Jaffray	Overweight
2019-02-28	Bestätigt	Chardan Capital Markets	Buy
2019-02-07	Eingeleitet	Robert W. Baird	Outperform
2018-12-31	Fortgesetzt	B. Riley FBR	Buy
2018-07-06	Bestätigt	Chardan Capital Markets	Buy
2018-04-10	Hochstufung	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Bestätigt	B. Riley FBR, Inc.	Neutral
2018-02-23	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Bestätigt	H.C. Wainwright	Buy
2017-11-01	Bestätigt	B. Riley FBR, Inc.	Buy

Alle ansehen

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

Dec 13, 2025

What analysts say about Iovance Biotherapeutics Inc 2LB stockLong-Term Investment Plans & Advanced Stock Screening Tools - earlytimes.in

Dec 13, 2025

Dec 08, 2025

Iovance Biotherapeutics (IOVA): Is the Market Overlooking a Potential Rebound in Valuation After a Tough Year? - Yahoo Finance

Dec 08, 2025

Weighing Iovance Biotherapeutics After a 71.8% Slide and DCF Upside in 2025 - Yahoo Finance

Dec 08, 2025

Voss Capital LP Acquires New Shares in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat

Dec 08, 2025

Dec 07, 2025

With Iovance Biotherapeutics Stock Sliding, Have You Assessed The Risk? - Trefis

Dec 07, 2025

2 Stocks That Could Soar by 52% and 282%, According to Wall Street - Finviz

Dec 07, 2025

2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool

Dec 07, 2025

Dec 06, 2025

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail

Dec 06, 2025

Dec 05, 2025

What earnings margins imply for Iovance Biotherapeutics Inc. (2LB) stockWeekly Stock Analysis & Fast Momentum Stock Entry Tips - Newser

Dec 05, 2025

Why Iovance Biotherapeutics Inc. (2LB) stock benefits from AI revolutionJuly 2025 PostEarnings & Safe Capital Investment Plans - Newser

Dec 05, 2025

What technical charts say about Iovance Biotherapeutics Inc. stock2025 Price Action Summary & Reliable Entry Point Trade Alerts - Newser

Dec 05, 2025

Will Iovance Biotherapeutics Inc. stock recover faster than peersWeekly Stock Summary & Verified Entry Point Signals - Newser

Dec 05, 2025

Dec 04, 2025

How buyback programs support Iovance Biotherapeutics Inc. (2LB) stockInsider Selling & Free Verified High Yield Trade Plans - Newser

Dec 04, 2025

Why Iovance Biotherapeutics Inc. (2LB) stock is upgraded to buyMarket Activity Recap & Daily Technical Forecast Reports - Newser

Dec 04, 2025

What dividend safety rating applies to Iovance Biotherapeutics Inc. (2LB) stock2025 Earnings Surprises & Weekly Return Optimization Alerts - Newser

Dec 04, 2025

Cash per share of Iovance Biotherapeutics Inc – DUS:2LB - TradingView

Dec 04, 2025

Why Iovance Biotherapeutics Inc. (2LB) stock is listed among top recommendationsChart Signals & Community Trade Idea Sharing Platform - Newser

Dec 04, 2025

Is Iovance Biotherapeutics Inc. (2LB) stock ideal for retirement investors2025 Fundamental Recap & Precise Trade Entry Recommendations - Newser

Dec 04, 2025

Dec 03, 2025

Officer Graf Finckenstein Acquires 6,247 Of Iovance Biotherapeutics Inc [IOVA] - TradingView

Dec 03, 2025

Officer Puri Acquires 3,002 Of Iovance Biotherapeutics Inc [IOVA] - TradingView

Dec 03, 2025

Iovance Biotherapeutics (NASDAQ: IOVA) officer reports RSU vesting and tax withholding on Form 4 - Stock Titan

Dec 03, 2025

Why Iovance Biotherapeutics Inc. stock remains undervaluedJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - Newser

Dec 03, 2025

Iovance Biotherapeutics Stock Hits Day Low of $2 Amid Price Pressure - Markets Mojo

Dec 03, 2025

Dec 02, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.9%What's Next? - MarketBeat

Dec 02, 2025

FINAL REMINDER IOVA DEADLINE: Bronstein, Gewirtz & Grossman LLC A - The National Law Review

Dec 02, 2025

Class Action Lawsuit Filed: Iovance Biotherapeutics, Inc. (IOVA)Join by July 14, 2025Contact Levi & Korsinsky - The National Law Review

Dec 02, 2025

Dec 01, 2025

Iovance Biotherapeutics Stock Dips Amid Market Reactions - StocksToTrade

Dec 01, 2025

Virtus Investment Advisers LLC Increases Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat

Dec 01, 2025

Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights

Dec 01, 2025

Nov 30, 2025

Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc - The National Law Review

Nov 30, 2025

IOVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Nov 30, 2025